title: Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
abstract: OBJECTIVE
  To compare postprandial efficacy in type 2 diabetic patients given mitiglinide and sitagliptin, both of which are known to improve postprandial hyperglycemia, by using continuous glucose monitoring (CGM).
  
  
  METHODS
  Eleven patients with type 2 diabetes were given mitiglinide 10 mg three times a daily or sitagliptin 50 mg once a day for 1 month and were hospitalized for 4 days and evaluated by CGM. On discharge, they were crossed over to the other regimen for 1 month of treatment/4 days of evaluation. The CGM data were used to compare each parameter for glycemic variability.
  
  
  RESULTS
  The patients were 60 ± 10 (mean ± SD) years old, and had HbA1c value 7.3 ± 0.9%. The pre-meal glucose levels before lunch were significantly lower with mitiglinide than with sitagliptin (116 ± 26/131 ± 34 mg/dl, p = 0.022). The AUC measuring over 140 mg/dl 3 h after breakfast (mitiglinide 4812 ± 4219/sitagliptin 7807 ± 6391 mg/dl·min, p = 0.042) and lunch (mitiglinide 5658 ± 5856/sitagliptin 8492 ± 7161, p = 0.050) was significantly lower with mitiglinide than with sitagliptin.
  
  
  CONCLUSIONS
  A CGM-based comparison showed that mitiglinide and sitagliptin were different in their glucose-lowering effects, where mitiglinide significantly improved hyperglycemia after breakfast and lunch, and significantly lowered pre-meal glucose levels before lunch, compared to sitagliptin.
authors.affiliation: Jikei University School of Medicine, Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine , 3-19-18 Nishishimbashi, Minato-ku, Tokyo 105-8471 , Japan rimei@jikei.ac.jp.
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Ando
authors.forename: Rimei
authors.initials: R
authors.lastname: Nishimura
authors.forename: Chiaki
authors.initials: C
authors.lastname: Seo
authors.forename: Daisuke
authors.initials: D
authors.lastname: Tsujino
authors.forename: Masaya
authors.initials: M
authors.lastname: Sakamoto
authors.forename: Kazunori
authors.initials: K
authors.lastname: Utsunomiya
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D054833:Isoindoles / Q000627:therapeutic use*; D008875:Middle Aged; D010865:Pilot Projects; D019518:Postprandial Period; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D054833:Isoindoles; D011719:Pyrazines; D014230:Triazoles; C087255:mitiglinide; D000068900:Sitagliptin Phosphate
keywords: clinical trial; continuous glucose monitoring; mitiglinide; postprandial glucose; sitagliptin; type 2 diabetes